Last reviewed · How we verify
Up to 900 micrograms Nexvax2 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Up to 900 micrograms Nexvax2 (Up to 900 micrograms Nexvax2) — Nexpep Pty Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Up to 900 micrograms Nexvax2 TARGET | Up to 900 micrograms Nexvax2 | Nexpep Pty Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Up to 900 micrograms Nexvax2 CI watch — RSS
- Up to 900 micrograms Nexvax2 CI watch — Atom
- Up to 900 micrograms Nexvax2 CI watch — JSON
- Up to 900 micrograms Nexvax2 alone — RSS
Cite this brief
Drug Landscape (2026). Up to 900 micrograms Nexvax2 — Competitive Intelligence Brief. https://druglandscape.com/ci/up-to-900-micrograms-nexvax2. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab